ইস্রায়েল - হিব্রু - Ministry of Health

astrazeneca (israel) ltd - tremelimumab - תרכיז להכנת תמיסה לאינפוזיה - tremelimumab 20 mg / 1 ml - tremelimumab

ইস্রায়েল - হিব্রু - Ministry of Health

taro international ltd, israel - esomeprazole - טבליה - esomeprazole 20 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

ইস্রায়েল - হিব্রু - Ministry of Health

taro international ltd, israel - esomeprazole - טבליה - esomeprazole 40 mg - esomeprazole - esomeprazole - nexium tablets are indicated for: gastroesophageal reflux disease (gerd): - treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease (gerd). in combination with an appropriate antibacterial therapeutic regimen for the eradication of helicobacter pylori and: - healing of helicobacter pylori associated duodenal ulcer and - prevention of relapse of peptic ulcers in patients with helicobacter pylory associated ulcers. - healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy in patients at risk.prolonged treatment after i.v induced prevention of rebleeding of peptic ulcers.

ইস্রায়েল - হিব্রু - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ইস্রায়েল - হিব্রু - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ইস্রায়েল - হিব্রু - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ইস্রায়েল - হিব্রু - Ministry of Health

astra zeneca israel ltd - exenatide 250 mcg/ml - solution for injection - exenatide - byetta is indicated as an adjunct to diet and exercise to improve glycimic control in adults with type 2 diabetes mellitus.byetta is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin or a sulfonylurea , alone or in combination, but have not achieved adequate glycemic control.

ইস্রায়েল - হিব্রু - Ministry of Health

astra zeneca israel ltd - a/california/7/2009 (h1n1) 7±0.5 log 10 ffu / 0.2 ml; a/victoria/361/2011 (h3n2) 7±0.5 log 10 ffu / 0.2 ml - internasal spray - influenza, inactivated, whole virus - flumist is a vaccine indicated for the active immunization of individuals 2- 49 years of age against influenza disease caused by influenza virus subtypes a and type b contained in the vaccine.

ইস্রায়েল - হিব্রু - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

ইস্রায়েল - হিব্রু - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.